Mackenzie Financial Corp Sells 258,526 Shares of Becton, Dickinson and Company (NYSE:BDX)

Mackenzie Financial Corp reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,333,449 shares of the medical instruments supplier’s stock after selling 258,526 shares during the period. Mackenzie Financial Corp’s holdings in Becton, Dickinson and Company were worth $545,350,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Jennison Associates LLC lifted its stake in shares of Becton, Dickinson and Company by 4.9% in the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock worth $99,562,000 after acquiring an additional 18,786 shares during the period. Norden Group LLC boosted its position in shares of Becton, Dickinson and Company by 2,086.7% during the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after purchasing an additional 49,559 shares in the last quarter. Franklin Street Advisors Inc. NC acquired a new stake in Becton, Dickinson and Company during the first quarter worth approximately $11,998,000. Avity Investment Management Inc. increased its holdings in Becton, Dickinson and Company by 3.5% in the first quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock worth $40,257,000 after purchasing an additional 5,527 shares in the last quarter. Finally, Caden Capital Partners LP grew its position in shares of Becton, Dickinson and Company by 26.7% during the 4th quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock worth $20,340,000 after buying an additional 17,599 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on BDX shares. Stifel Nicolaus increased their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Evercore ISI cut their target price on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Citigroup reduced their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $279.50.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $237.26 on Friday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $269.52. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The stock has a 50-day simple moving average of $235.94 and a two-hundred day simple moving average of $235.50. The firm has a market capitalization of $68.57 billion, a P/E ratio of 52.26, a PEG ratio of 1.92 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same period in the previous year, the business posted $2.96 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 2.3% on a year-over-year basis. On average, equities analysts forecast that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.